Shubham Prashant Badadhe
Research Subjects
Shubham Prashant Badadhe has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Pravin Vishnu Badadhe
P. G. Department of Chemistry and Research Centre, R. B. Narayanrao Borawake College, Shrirampur, M.S., India 413709
2 shared publications - Aruna S. Shinde
P. G. Department of Chemistry and Research Centre, R. B. Narayanrao Borawake College, Shrirampur, M.S., India 413709
1 shared publication Ashis Nandy
1 shared publication- Marian Hajduch
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, 77900 Olomouc, Czech Republic
1 shared publication Pallavi B. Darekar
R. B. Narayanrao Borawake College Shrirampur Maharashtra India
1 shared publication- Petr Džubák
Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc Olomouc Czech Republic
1 shared publication
Latest Publications
- 8 October 2026
- Published by Wiley in Journal of Peptide Science
- Vol. 32 (11)
Greener Liquid‐Phase Synthesis of Pseudoproline Dipeptide Building Blocks in Ethanol and Water
A sustainable synthetic strategy for Fmoc‐protected pseudoproline dipeptides was developed to address the environmental and operational limitations of traditional solvent‐intensive methods. By utilizing ethanol as solvent during cyclisation, activated ester formation, and coupling steps, this approach eliminates the need for hazardous conventional solvents while simplifying the overall process. The protocol consistently delivers pseudoproline dipeptides in high yields and with excellent purity, demonstrating that environmentally friendly modifications can maintain strong synthetic performance. In addition to its operational simplicity and scalability, the method significantly reduces solvent‐related hazards, minimizes waste generation, and improves key green chemistry. This practical and versatile methodology provides a cleaner, more sustainable platform for the synthesis of pseudoproline‐containing intermediates relevant to peptide and pharmaceutical manufacturing.
- 8 October 2026
- Published by Wiley in Journal of Peptide Science
- Vol. 32 (11)
Greener Liquid‐Phase Synthesis of Pseudoproline Dipeptide Building Blocks in Ethanol and Water
A sustainable synthetic strategy for Fmoc‐protected pseudoproline dipeptides was developed to address the environmental and operational limitations of traditional solvent‐intensive methods. By utilizing ethanol as solvent during cyclisation, activated ester formation, and coupling steps, this approach eliminates the need for hazardous conventional solvents while simplifying the overall process. The protocol consistently delivers pseudoproline dipeptides in high yields and with excellent purity, demonstrating that environmentally friendly modifications can maintain strong synthetic performance. In addition to its operational simplicity and scalability, the method significantly reduces solvent‐related hazards, minimizes waste generation, and improves key green chemistry. This practical and versatile methodology provides a cleaner, more sustainable platform for the synthesis of pseudoproline‐containing intermediates relevant to peptide and pharmaceutical manufacturing.
- Open Access
- 18 June 2026
- Published by Elsevier in SSRN Electronic Journal
Novel N-(4-(Chlorodifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives: Design, Synthesis, Molecular Modeling Investigation and Anticancer Activity in various cell lines
A novel series of N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives (9a–9p) were synthesized and tested for anticancer activity against multiple human cancer cell lines including K562, A549, CCRF-CEM, HCT116, HCT116 p53−/−, U2OS along with normal human fibroblast cell lines BJ and MRC-5. Significant emphasis was placed on the K562 cell line, an established model for BCR-ABL1-positive Chronic Myeloid Leukemia. Compound 9c has good potency with an IC₅₀ value of 0.22 ± 0.034 µM and selectivity (SI >100) against normal fibroblast cells such as BJ and MRC-5 cell lines. Compounds 9a (IC₅₀ = 0.82 ± 0.091 µM), followed by 9k (0.53 ± 0.04 µM), 9l (0.91 ± 0.092 µM) and 9b (0.98 ± 0.18 µM) showed good activity with favourable selectivity index (>30), however the reference drug Asciminib has remained superior with an IC50 value of 0.005 ± 0.001 µM and selectivity index value of >10000. Overall, the good activity of these compounds against K562 cells suggests a possible BCR-ABL1-related mechanism. Molecular docking studies revealed good binding affinities, with compound 9b showing the good Glide score (−8.11 kcal/mol). Although enzyme inhibition assays were not conducted but the observed selective cytotoxicity in K562 cells indicates potential modulation of BCR-ABL1 mediated signalling pathways.
- 18 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNovel N-(4-(Chlorodifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives: Design, Synthesis, Molecular Modeling Investigation and Anticancer Activity in various cell lines
A novel series of N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives (9a–9p) were synthesized and tested for anticancer activity against multiple human cancer cell lines including K562, A549, CCRF-CEM, HCT116, HCT116 p53−/−, U2OS along with normal human fibroblast cell lines BJ and MRC-5. Significant emphasis was placed on the K562 cell line, an established model for BCR-ABL1-positive Chronic Myeloid Leukemia. Compound 9c has good potency with an IC₅₀ value of 0.22 ± 0.034 µM and selectivity (SI >100) against normal fibroblast cells such as BJ and MRC-5 cell lines. Compounds 9a (IC₅₀ = 0.82 ± 0.091 µM), followed by 9k (0.53 ± 0.04 µM), 9l (0.91 ± 0.092 µM) and 9b (0.98 ± 0.18 µM) showed good activity with favourable selectivity index (>30), however the reference drug Asciminib has remained superior with an IC50 value of 0.005 ± 0.001 µM and selectivity index value of >10000. Overall, the good activity of these compounds against K562 cells suggests a possible BCR-ABL1-related mechanism. Molecular docking studies revealed good binding affinities, with compound 9b showing the good Glide score (−8.11 kcal/mol). Although enzyme inhibition assays were not conducted but the observed selective cytotoxicity in K562 cells indicates potential modulation of BCR-ABL1 mediated signalling pathways.